AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to beryllium acquired by Eli Lilly and Co (NYSE:LLY) successful a transaction valued astatine up to astir $3.8 billion, with the woody adding the clinical-stage biotechnology company's pipeline of investigational therapies for treatment-resistant slump and different intelligence wellness conditions to Lilly's neuroscience portfolio.

Under the presumption of the agreement, Lilly volition wage $6.75 per stock successful currency astatine closing, representing an aggregate equity worth of astir $2.8 billion.

Shareholders volition besides person contingent worth rights (CVRs) worthy up to an further $2.50 per stock if specified clinical, regulatory and commercialization milestones for AtaiBeckley's pb programs are achieved, bringing the imaginable full equity worth to astir $3.8 billion.

The acquisition terms represents a premium of astir 40% to AtaiBeckley's 30-day volume-weighted mean stock terms done July 15, 2026, according to Lilly.

Lilly said the acquisition would fortify its neuroscience portfolio by adding therapies designed to reconstruct synaptic connectivity, an attack that differs from accepted antidepressants that chiefly people neurotransmitter levels.

AtaiBeckley's pb candidate, BPL-003, is an intranasal synthetic signifier of 5-MeO-DMT being developed for treatment-resistant depression. The institution said the therapy demonstrated accelerated and durable reductions successful depressive symptoms successful a Phase 2b proceedings and has received Breakthrough Therapy Designation from the US Food and Drug Administration. Phase 3 activities person begun.

The company's 2nd astir precocious program, VLS-01, is simply a buccal movie formulation of DMT that is presently being evaluated successful a Phase 2b study.

"Treatment-resistant slump persists adjacent aft aggregate treatments person failed. Millions of radical are inactive searching for alleviation and desperately request a therapy that works," Carole Ho, enforcement vice president and president of Lilly Neuroscience, said successful a statement.

"Advancing AtaiBeckley's investigational therapies gives america a existent accidental to alteration that."

AtaiBeckley main enforcement serviceman and co-founder Srinivas Rao said the transaction could accelerate improvement of the company's pipeline.

"Across our portfolio, we're seeking to show that psychiatric unwellness is treatable astatine its biologic root, not conscionable its symptoms," Rao said. "Lilly's expertise and scope are expected to accelerate that enactment for radical whose conditions person not responded to existing treatments."

Christian Angermayer, founder, largest shareholder and president of AtaiBeckley, said the woody represented "the champion way guardant for patients and shareholders."